Latest Regulatory Review News

Telix Pharmaceuticals has announced FDA acceptance of its resubmitted NDA for TLX101-Px (Pixclara®), a PET imaging agent for glioma, setting a PDUFA goal date of September 11, 2026. The agent addresses a significant unmet need in distinguishing recurrent glioma from treatment effects.

Algorae Pharmaceuticals has reached a key regulatory milestone as the TGA accepts its initial registration dossier, paving the way for potential commercialisation of its generic medicines in Australia and New Zealand.

PMET Resources has submitted the Environmental and Social Impact Assessment for its Shaakichiuwaanaan CV5 Lithium Project, marking a pivotal step in securing regulatory approvals. This follows a positive feasibility study and extensive Indigenous engagement.

Optiscan Imaging Ltd has taken a significant step towards commercialising its InSpecta® veterinary imaging device in the US by submitting a regulatory dossier to the FDA. This milestone not only initiates formal review but also sets the stage for broader clinical adoption and future device approvals.

Echo IQ has strengthened its partnership with Mayo Clinic to distribute its AI-driven heart failure diagnostic tool, EchoSolv HF, pending FDA clearance. The expanded agreement offers a scalable commercial pathway across a vast US hospital network.

The Takeovers Panel has received a formal review application challenging its recent decision on Humm Group Limited, signaling potential further scrutiny of the corporate governance dispute.

Siren Gold’s latest drilling at its Sams Creek Project in New Zealand confirms significant gold mineralisation outside the established Main Zone, highlighting promising expansion potential along the 7km Sams Creek Dyke.

Identitii Limited’s ID8N securities have been reinstated to trading following the close of its recent rights issue and the resolution of a Takeovers Panel application.

Northern Minerals has withdrawn its Extraordinary General Meeting and obtained a court order to defer its 2025 AGM until June 30, 2026, allowing more time for regulatory review. This move supports progress toward a key investment decision for its Browns Range rare earths project.

Bio-Gene Technology Limited reports strong progress in toxicology studies for Flavocide, targeting its first regulatory submission in Australia by March 2027. This milestone sets the stage for global registrations of the novel insecticide with a new mode of action.

Recce Pharmaceuticals reported a doubling of its net loss for the half-year ended December 2025 amid significant progress in its anti-infective drug development and a substantial funding boost. The company is advancing Phase 3 trials and expanding its patent portfolio while managing financial pressures.

Polymetals Resources has reported its maiden revenue from the Endeavor Mine with first concentrate shipments, yet posted a substantial half-year loss of $34.5 million. Operational setbacks and exploration advances mark a pivotal phase for the company.